Clinical Research Directory
Browse clinical research sites, groups, and studies.
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Summary
T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.
Official title: Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2019-01-01
Completion Date
2035-01-01
Last Updated
2024-06-26
Healthy Volunteers
No
Interventions
ITNK cell therapy
Infusion of ITNK/CAR-ITNK cells
Locations (1)
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China